Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications.
Saidu NE, Noé G, Cerles O, Cabel L, Kavian-Tessler N, Chouzenoux S, Bahuaud M, Chéreau C, Nicco C, Leroy K, Borghese B, Goldwasser F, Batteux F, Alexandre J. Saidu NE, et al. Among authors: leroy k. Mol Cancer Ther. 2017 Mar;16(3):529-539. doi: 10.1158/1535-7163.MCT-16-0405. Epub 2017 Jan 9. Mol Cancer Ther. 2017. PMID: 28069874
Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.
Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S. Heidelberger V, et al. Among authors: leroy k. Invest New Drugs. 2017 Aug;35(4):436-441. doi: 10.1007/s10637-017-0464-x. Epub 2017 Apr 10. Invest New Drugs. 2017. PMID: 28396974
Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.
Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S. Heidelberger V, et al. Among authors: leroy k. Invest New Drugs. 2017 Aug;35(4):537. doi: 10.1007/s10637-017-0475-7. Invest New Drugs. 2017. PMID: 28597150 No abstract available.
Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells.
Bennett Saidu NE, Bretagne M, Mansuet AL, Just PA, Leroy K, Cerles O, Chouzenoux S, Nicco C, Damotte D, Alifano M, Borghese B, Goldwasser F, Batteux F, Alexandre J. Bennett Saidu NE, et al. Among authors: leroy k. Oncotarget. 2018 Jan 10;9(10):9088-9099. doi: 10.18632/oncotarget.24144. eCollection 2018 Feb 6. Oncotarget. 2018. PMID: 29507676 Free PMC article.
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.
Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D. Biton J, et al. Among authors: leroy k. Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15. Clin Cancer Res. 2018. PMID: 29764856
BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine.
Tlemsani C, Pasmant E, Boudou-Rouquette P, Bellesoeur A, Even J, Larousserie F, Reyes C, Gentien D, Alexandre J, Vidaud M, Anract P, Leroy K, Goldwasser F. Tlemsani C, et al. Among authors: leroy k. Am J Med Sci. 2018 Oct;356(4):404-407. doi: 10.1016/j.amjms.2018.04.015. Epub 2018 May 1. Am J Med Sci. 2018. PMID: 30041945 Review.
[Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
Lupo A, Alifano M, Wislez M, Boulle G, Velut Y, Biton J, Cremer I, Goldwasser F, Leroy K, Damotte D. Lupo A, et al. Among authors: leroy k. Rev Pneumol Clin. 2018 Oct;74(5):339-350. doi: 10.1016/j.pneumo.2018.09.010. Epub 2018 Oct 15. Rev Pneumol Clin. 2018. PMID: 30337201 Review. French.
Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options.
Tlemsani C, Leroy K, Gimenez-Roqueplo AP, Mansuet-Lupo A, Pasmant E, Larousserie F, Boudou-Rouquette P, Vidaud M, Cadranel J, Blons H, Goldwasser F, Laurent-Puig P. Tlemsani C, et al. Among authors: leroy k. J Med Genet. 2020 Feb;57(2):104-108. doi: 10.1136/jmedgenet-2018-105594. Epub 2018 Oct 23. J Med Genet. 2020. PMID: 30352869
210 results